Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

[Q]: Paragraph: Use of such pills, which include Sanofi SA’s Ambien and other similar drugs, was significantly higher for those in their 50s as well as age 80 and older, according to the findings from the Centers for Disease Control and Prevention. Overall about 8.6 million people, or 4 percent of U.S. adults reported recently using sleep medication, CDC’s National Center for Health Statistics said in a report. But data showed higher use among middle-aged adults ages 50 to 59 and the elderly. Six percent of those ages 50 to 59 said they had taken a prescription sleep pill in the last 30 days, and 7 percent of those age 80 and older reported such use. In between, the numbers dip slightly below 6 percent for those in their 60s and 70s. In comparison, just 2 percent of those aged 20-39 said they had recently taken a sleep aid. CDC researcher Yinong Chong said people in their 50s could have trouble sleeping because of work and family stress. “It gives the picture of a sandwiched group who has family, not only children but also probably elderly parents but still you’re likely to be in the workforce, so you get squeezed at both ends in terms of family responsibility and job responsibility,” she said. Sleep may improve when people retire before potential chronic health problems kick in and begin interfering with sleep, Chong said, adding more study is needed. The data also showed that 5 percent of women surveyed said they had recently taken a sleep aid compared to about 3 percent of male respondents, according to CDC’s report. Chong said it was not clear why women were more likely to use the drugs. While previous data have tracked prescriptions dispensed for sleep aids, the CDC said its study is the first based on a survey of actual use of such drugs. Researchers for the Atlanta-based health agency’s National Center for Health Statistics questioned a sampling of adults age 20 and older about whether they had used prescription sleep aids within the last 30 days and asked participants to show interviewers the prescription medication. “You get how many people are actually using them,” Chong said in an interview, noting that prescription data could include multiple prescriptions for one patient or prescriptions that are never filled or even used. “This is actual use.”  Prescription sleep aids have become somewhat controversial because their effect can linger even after some patients wake up. The U.S. Food and Drug Administration has begun taking a closer look at sleep drugs, ordering lower-doses for Ambien and similar pills amid concerns that their active ingredient remained in patients’ blood the following morning at levels high enough to make driving and other activities dangerous. And just last month, the FDA rejected an experimental sleep drug from Merck & Co Inc, saying the proposed doses were not safe but that a lower-dose version might be acceptable. Not surprisingly, respondents to CDC’s study who said they slept five hours or less each night or those diagnosed with a sleep disorder were more likely to report using prescription aids. Additionally, more whites and people with higher levels of education also reported greater use, the agency said. Socioeconomic factors are likely behind those numbers, Chong said, since patients must be able to afford a doctor’s care and the medication. According to prescription data from IMS Health, Ambien and other versions of the drug zolpidem was ranked 15th among the most dispensed medications in the United States. Claim: Use of sleeping pills highest among older Americans: CDC.
[A]: Older U.S. adults, particularly women, are more likely to use prescription sleep medications to try to get the minimum seven hours of sleep experts generally recommend, U.S. data released on Thursday showed.


[Q]: Paragraph: Major U.S. indexes fell about 2 percent and the Dow Jones Industrial Average dropped as much as 563 points. On the benchmark S&P 500 index, health care and technology companies absorbed the worst losses. Johnson & Johnson plunged by the most in 16 years after Reuters reported that the company has known since the 1970s that its talc Baby Powder sometimes contained carcinogenic asbestos. The company denied the report. China said industrial output and retail sales both slowed in November. That could be another sign that China’s trade dispute with the U.S. and tighter lending conditions are chilling its economy, which is the second-largest in the world. Meanwhile, purchasing managers in Europe signaled that economic growth was slipping. Sameer Samana, senior global market strategist for Wells Fargo Investment Institute, said investors are concerned that weakness will make it way to the U.S. They’re wondering if the U.S. economy is likely to run out of steam sooner than they had thought. “Market consensus has been that the next recession is probably in 2020 or beyond,” he said. Now, he said, the market is “really testing that assumption and trying to figure out whether it’s sooner.” Rising interest rates and tighter credit conditions are adding to investors’ nervousness because they both tend to slow down economic growth. This week the European Central Bank said it is ending a bond-buying program that has pumped trillions into Europe’s economy. The Federal Reserve is expected to increase U.S. rates again on Wednesday, as it’s been doing for the last three years. It may also shed light on whether it plans to raise rates further in 2019. For more than 20 years, China has been one of the biggest contributors to growth in the global economy, and when investors see signs the Chinese economy is weakening, they expect it will affect other countries like the U.S. that sell things to China. In Europe, the index of purchase managers fell in France, which is racked by protests, to a level that points toward economic contraction. Germany’s reading still pointed to growth, but it fell to its lowest level in four years. Those reports canceled out some potential good news on trade: the Chinese government announced a 90-day suspension of tariff increases on U.S. cars, trucks and auto imports. It’s part of a cease-fire that China and the U.S. announced earlier this month to give them time to work on other issues. December is typically the best month of the year for stocks as a “Santa Claus rally” often adds to the year’s gains. With 10 trading days left this month, however, the S&P 500 is down 5.8 percent. That followed a small gain in November and a steep 6.9 percent drop in October. The S&P 500 index lost 50.59 points, or 1.9 percent, to 2,599.95, its lowest close since April 2. The Dow retreated 496.87 points, or 2 percent, to 24,100.51. The Dow has fallen 10 percent from its record high in early October, reaching a mark known on Wall Street as a “correction.” The other major U.S. indexes were already in “corrections.” The Nasdaq composite slid 159.67 points, or 2.3 percent, to 6,910.66. The Russell 2000 index of smaller-company stocks fell 21.89 points, or 1.5 percent, to 1,410.81. Johnson & Johnson dropped 10 percent to $133 in very heavy trading. Its market value fell by $40 billion. Reuters reported that court documents and test results show Johnson & Johnson has known for decades that its raw talc and finished Baby Powder sometimes contained asbestos, but that the company didn’t inform regulators or the public. The company called the story “false and inflammatory.” In July the company lost a lawsuit from plaintiffs who argued that its products were linked to cases of ovarian cancer and mesothelioma. A St. Louis jury awarded plaintiffs $4.7 billion. Johnson & Johnson faces thousands of other lawsuits. Among technology companies, Apple dipped 3.2 percent to $165.48. Adobe skidded 7.3 percent to $230 after its fourth-quarter profit disappointed investors and it also forecast lower-than-expected earnings in the current fiscal year. Industrial companies sank as well. Boeing lost 2.1 percent to $318.75. Oil prices again turned lower, as a slower global economy would weaken demand for oil and other fuels. Benchmark U.S. crude fell 2.6 percent to $51.20 a barrel in New York. Brent crude, used to price international oils, dropped 1.9 percent to settle at $60.28 a barrel in London. European Union leaders rejected British Prime Minister Theresa May’s request to make changes to their deal covering Britain’s departure from the EU on March 29. British legislators aren’t satisfied with the terms May negotiated, and she canceled a scheduled vote earlier this week because it was clear Parliament wouldn’t approve it. Britain’s economy and financial markets across Europe face severe disruption without an agreement. In other trading: —European bond prices rose and yields fell. Both the British pound and the euro weakened. The pound slipped to $1.2579 from $1.2660 and the euro fell to $1.1303 from $1.1367. —Germany’s DAX declined 0.5 percent and the CAC 40 in France declined 0.8 percent. Britain’s FTSE 100 fell 0.5 percent. —Japan’s Nikkei 225 index slid 2 percent and the Kospi in South Korea lost 1.3 percent. Hong Kong’s Hang Seng was down 1.6 percent. —Bond prices edged higher. The yield on the 10-year Treasury note fell to 2.89 percent 2.90 percent. —In other commodities trading, wholesale gasoline lost 3 percent to $1.43 a gallon. Heating oil fell 1.7 percent to $1.85 a gallon and natural gas dropped 7.2 percent to $3.83 per 1,000 cubic feet. —Gold fell 0.5 percent to $1,241.40 an ounce. Silver dipped 1.5 percent to $14.64 an ounce. Copper was little changed at $2.77 a pound. —The dollar fell to 113.29 yen from 113.60 yen. ____ Associated Press Writer Josh Boak contributed to this report from Washington. ___ AP Markets Writer Marley Jay can be reached at http://twitter.com/MarleyJayAP Claim: Stocks plunge to 8-month lows on growth fears; J&J nosedives.
[A]: Stocks staggered to eight-month lows Friday after weak economic data from China and Europe set off more worries about the global economy. Mounting tensions in Europe over Britain’s impending departure from the European Union also darkened traders’ moods.


[Q]: Paragraph: The story sidebar estimates that a full course of treatment can cost $3000 or more. It could have added that this treatment is unlikely to be covered by many insurance companies. This was the biggest hole in an otherwise reasonably solid story. The article claims that there is “growing evidence” that neurofeedback can help treat people with ADHD. However, the story never describes any of the results of this purported increase in research that supposedly documents these benefits. The closest we come is the description of a study which hasn’t even been published yet. The story also suggests that neurofeedback’s benefits might last longer than those of medication. Again, however, we are never given any sound basis to believe that neurofeedback works at all — let alone better than other treatments. At the same time, the story leans heavily on testimony from a journalist who has written a book about ADHD and claims neurofeedback worked for her and her son. We are told that the primary improvement she saw with her son was that he was “easier to live with.” Although this kind of anecdotal report can be useful to add context to scientific findings, it is certainly no substitute for reporting on the actual clinical outcomes of research. The story failed to discuss any potential harms of neurofeedback treatment. The most prominent of these is that patients could forego other treatment approaches that have better supporting evidence and are more likely to reduce symptoms. There is also some evidence that neurofeedback can cause seizures or make symptoms worse in some individuals with psychological disorders. In addition, the need for frequent treatments may necessitate taking a child out of school. Readers should come away from this story with a generally accurate feel for where the research on this treatment stands. The story told readers early on that neurofeedback is “scientifically uNPRoved” for the treatment of ADHD. It backs up this contention later in this story by noting that almost all research on this treatment hasn’t involved a placebo control group. And the only study to include such a group apparently hasn’t released its results yet and seems to have involved a very small number of patients. In addition, the story quotes an expert who emphasizes that other forms of treatment (e.g. medication and behavior therapy) have better evidence to support their effectiveness for ADHD. We did think the story focused a bit too much on a single patient anecdote (a deficiency discussed later under the “Benefits” criterion) — an emphasis which makes the treatment sound very promising with little justification. The story could have struck a better balance by toning this section down a bit. No disease-mongering in this story. In addition to extensive comments from the journalist book author who discusses her experience with neurofeedback, the story quotes a Duke University researcher who is an expert on ADHD and offers some counterbalancing perspective. The story quotes a researcher who says that two other approaches — medication and behavior therapy — have a more extensive research base supporting their use for ADHD compared with neurofeedback. It’s clear from the story that this type of treatment is available to the general public. We like that the story cautioned readers to look out for unqualified therapists and gave tips for finding reputable clinicians. The story could have been more specific about how many trained professionals there are and how easy it is to find them outside of large population centers. The story does not oversell the novelty of neurofeedback for the treatment of ADHD. This story does not appear to be based on a news release. Claim: Train The Brain: Using Neurofeedback To Treat ADHD
[A]:
The story did accurately portray the overall state of the evidence on neurofeedback for ADHD and emphasized the lack of well controlled studies supporting its effectiveness. It also provided useful information about how to avoid untrained therapists, and was generally good in its approach to the other criteria that we look at. In the final analysis, the story applied the healthy skepticism which is a hallmark of good journalism to this topic. But a significant flaw at its core makes this story less useful than it could have been and makes us wonder why it was considered newsworthy, since there is apparently no compelling recent research to discuss. It might have been better to wait for the results of the first placebo-controlled study of neurofeedback for children with ADHD (which the story says will be out in just a few weeks) to be published. For many parents, medication is not an appealing option for treating a child’s ADHD symptoms. The availability of better non-pharmacologic alternatives would therefore be an important and welcome development. Journalists have to be careful about how they characterize the research supporting uNPRoven approaches such as neurofeedback, however. If there’s evidence that a treatment is effective, we should expect to hear descriptions of the relevant studies and estimates of how big the benefits are for which specific outcomes.